CLINICAL TRIALS PROFILE FOR CLINORIL
✉ Email this page to a colleague
All Clinical Trials for CLINORIL
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00005882 ↗ | Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps | Completed | Chao Family Comprehensive Cancer Center | Phase 3 | 1998-07-01 | This randomized phase III trial is studying eflornithine and sulindac to see how well they work compared to a placebo in preventing colorectal cancer in patients with colon polyps. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of eflornithine and sulindac may prevent colorectal cancer. It is not yet known whether eflornithine and sulindac are more effective than a placebo in preventing colorectal cancer |
NCT00005882 ↗ | Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps | Completed | National Cancer Institute (NCI) | Phase 3 | 1998-07-01 | This randomized phase III trial is studying eflornithine and sulindac to see how well they work compared to a placebo in preventing colorectal cancer in patients with colon polyps. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of eflornithine and sulindac may prevent colorectal cancer. It is not yet known whether eflornithine and sulindac are more effective than a placebo in preventing colorectal cancer |
NCT00005882 ↗ | Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps | Completed | University of California, Irvine | Phase 3 | 1998-07-01 | This randomized phase III trial is studying eflornithine and sulindac to see how well they work compared to a placebo in preventing colorectal cancer in patients with colon polyps. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of eflornithine and sulindac may prevent colorectal cancer. It is not yet known whether eflornithine and sulindac are more effective than a placebo in preventing colorectal cancer |
NCT00062023 ↗ | Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer | Terminated | National Cancer Institute (NCI) | Phase 2 | 2003-06-01 | RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known whether sulindac, aspirin, or ursodiol is more effective in preventing colorectal cancer. PURPOSE: This randomized phase II trial is studying how well sulindac works compared to aspirin or ursodiol in preventing colorectal cancer. |
NCT00062023 ↗ | Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer | Terminated | M.D. Anderson Cancer Center | Phase 2 | 2003-06-01 | RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known whether sulindac, aspirin, or ursodiol is more effective in preventing colorectal cancer. PURPOSE: This randomized phase II trial is studying how well sulindac works compared to aspirin or ursodiol in preventing colorectal cancer. |
NCT00068419 ↗ | Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor | Completed | National Cancer Institute (NCI) | Phase 2 | 2004-02-01 | This phase II trial is studying how well giving sulindac together with tamoxifen works in treating patients with desmoid tumor. Sulindac may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Hormone therapy using tamoxifen may fight cancer by blocking the use of estrogen. Combining sulindac with tamoxifen may kill more cancer cells. |
NCT00068419 ↗ | Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor | Completed | Children's Oncology Group | Phase 2 | 2004-02-01 | This phase II trial is studying how well giving sulindac together with tamoxifen works in treating patients with desmoid tumor. Sulindac may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Hormone therapy using tamoxifen may fight cancer by blocking the use of estrogen. Combining sulindac with tamoxifen may kill more cancer cells. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CLINORIL
Condition Name
Clinical Trial Locations for CLINORIL
Trials by Country
Clinical Trial Progress for CLINORIL
Clinical Trial Phase
Clinical Trial Sponsors for CLINORIL
Sponsor Name